Results 121 to 130 of about 7,608 (177)

Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves' orbitopathy. [PDF]

Eur Thyroid J
Bartalena L, Gallo D, Kahaly GJ, Marinò M, Tanda ML.   +4 more
europepmc   +1 more source

Graves' orbitopathy following Alemtuzumab treatment for multiple sclerosis: a systematic review and real-world insights. [PDF]

Thyroid Res
Patera B, Zaffaroni A, Louka S, Gallo D, Piantanida E, Tanda ML.   +5 more
europepmc   +1 more source

Pure Endoscopic Orbital Decompression in Graves' Orbitopathy: A Comprehensive Retrospective Analysis of Objective and Subjective Outcomes. [PDF]

Med Sci (Basel)
Almanzo S, Saro-Buendía M, Tortajada-Torralba I, Peris-Moreno C, España-Gregori E, Armengot M, García-Piñero A.   +6 more
europepmc   +1 more source

Real world effectiveness of Mycophenolate-sodium therapy in patients at risk with Graves' orbitopathy. [PDF]

Thyroid Res
Sander J, Al-Ghazzawi K, Bechrakis N, Chen Y, Neumann I, Eckstein A, Oeverhaus M.   +6 more
europepmc   +1 more source

Risk factors and outcomes of Graves' orbitopathy after radioactive iodine therapy. [PDF]

Endocrine
Ahn HY, Lee J, Kim M, Lee JK.
europepmc   +1 more source

Volumetric Analysis of Navigation-Guided Orbital Decompression in Graves' Orbitopathy: A Case Report. [PDF]

Life (Basel)
Ruiz-de-Leon G, Ochandiano S, Alvarez-Mokthari S, Benito-Anguita M, Nieva-Pascual I, Cifuentes-Canorea P, Sanjuan-de-Moreta G, Salmeron JI, Navarro-Cuellar I, Navarro-Cuellar C, Tousidonis M.   +10 more
europepmc   +1 more source

Autoimmune thyroid disease with myasthenia gravis in a 28-year-old male: a case report [PDF]

, 2009
Imran Masood, Mir Yasir, Aiffa Aiman, R P Kudyar   +3 more
core   +1 more source

Serum Biomarkers Linked to Disease Activity, Severity, and Methylprednisolone Response in Graves' Orbitopathy: A Proteomic Study. [PDF]

Invest Ophthalmol Vis Sci
Hötte GJ, Kolijn PM, de Bie M, Swagemakers SMA, van der Spek PJ, de Keizer ROB, Goudsmit BFJ, Visser WE, van Hagen PM, Paridaens D, Dik WA.   +10 more
europepmc   +1 more source

Retraction: Preliminary Evidence From an Original Study Suggests Combustion, Not Nicotine, Drives Risk and Complications of Graves' Orbitopathy. [PDF]

Cureus
Acanfora M, Vassallo A.
europepmc   +1 more source

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

J Clin Endocrinol Metab
Wolf J, Lorenz K, Othman AE, Beck A, Michel HM, Grauhan L, Elflein H, Luffy M, Eckstein A, Lahner H, Schittkowski M, Horn M, Lagrèze WA, Bleul T, Pitz S, Vorländer C, Pieterse CC, Porter B, Clemens A, Draikiwicz S, Reinhardt M, Kahaly GJ.   +21 more
europepmc   +1 more source